BioSpace News Archive

Nicox SA, an international ophthalmology company, announced the appointment of Doug Hubatsch to lead all of the Company’s non-clinical and clinical development activities.

Genentech, a member of the Roche Group, announced results from an interim analysis of the Phase III HAVEN 6 study, which show Hemlibra® demonstrated a favorable safety profile and effective bleed control in people with moderate or mild hemophilia A without factor VIII inhibitors.

Regeneron Pharmaceuticals, Inc. and Sanofi announced detailed positive Phase 3 results that showed adding Dupixent® to standard-of-care topical corticosteroids significantly improved skin clearance and reduced overall disease severity and itch in infants and children aged 6 months to 5 years with uncontrolled moderate-to-severe atopic dermatitis.

OKYO Pharma Limited is pleased to announce that its drug candidate OK-101 which was developed to treat DED through its anti-inflammatory mode of action also shows potent ocular pain reducing property determined using a mouse model of corneal neuropathic pain, establishing the potential to treat both pain and inflammation, the most common symptoms of dry eye, with a single drug.

Biosion, Inc., a global, clinical stage biotechnology company, announced that Biosion and OBI Pharma Inc. have signed an exclusive license agreement under which OBI Pharma will be granted a global exclusive license to Biosion’s proprietary anti-Trop2 humanized monoclonal antibody, BSI04702, for developing next generation biologics.

MediciNova, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).

Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases.

Halberd Corporation (OTC PINK:HALB) has demonstrated 100% eradication of Interleukin-1 (IL-1) from synthetic cerebral spinal fluid (CSF) in preliminary testing.

Equillium, Inc. today announced two poster presentations at the 63rd Annual Meeting of the American Society of Hematology.

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, to be held virtually from January 5-7, 2022.